Company Overview - SierraMedical, an innovative domestic ophthalmic medical device company, recently completed a new financing round exceeding 100 million yuan, led by Qianji Capital and Shunwei Capital, with existing shareholders Bohang Capital and Honghui Fund increasing their stakes [1] - Founded in July 2022, SierraMedical integrates research and development, production, and sales, focusing on providing precise and intelligent minimally invasive surgical solutions for ophthalmology [3] Product Development - The financing will primarily support the deep development of the company's first self-developed phacoemulsification and vitrectomy integrated machine product line, while also enriching the company's ophthalmic surgical equipment product matrix [1] - SierraMedical has launched the NEXVIT® series of ultra-high-speed dual-blade dual-gas path vitreous cutting heads, achieving a cutting speed of up to 20,000 cuts per minute, which has been clinically validated for performance and safety [3] - The company is also developing a disposable ophthalmic puncture device that features a slanted front cut and a chamfered design to assist surgeons in making precise and safe incisions, minimizing damage to surrounding eye tissue [4] Market Potential - The ophthalmic medical device market in China reached a scale of 45 billion yuan in 2023, with a compound annual growth rate exceeding 15%, significantly higher than the global average [3] - SierraMedical aims to break the monopoly of foreign companies in the high-end ophthalmic surgical instrument sector and address critical instrument supply issues [3] Investment Insight - Qianji Capital and Shunwei Capital, both leading investors in this financing round, have a strong track record in the medical field, with Qianji Capital being one of the earliest specialized funds in healthcare and life sciences in China [6]

Core Insights - The article discusses the completion of over 100 million yuan financing by the ophthalmic medical device innovation company, Siairan Medical, led by Qianji Capital and Shunwei Capital, with continued support from existing shareholders [1] Company Overview - Siairan Medical was established in July 2022 and integrates research, production, and sales, focusing on providing precise and intelligent minimally invasive surgical solutions for ophthalmology [1] - The core team possesses extensive industry experience and has a complete capability in research, production, and commercialization [1] Product Development - The financing will primarily be used for the in-depth development of the company's first self-developed phacoemulsification and vitrectomy integrated machine product line [1] - The company aims to enrich its ophthalmic surgical equipment product matrix and accelerate the import substitution of high-end ophthalmic devices and the international expansion of its products [1] Market Position - Siairan Medical is dedicated to breaking the monopoly of foreign companies in the high-end ophthalmic surgical instrument sector and addressing critical instrument supply issues [1] - Current research and development products include the phacoemulsification and vitrectomy integrated machine and its supporting consumables, as well as digital surgical microscopes [1] Financing History - To date, the company has completed three rounds of financing, each exceeding 100 million yuan [1]

Core Insights - Honghui Fund's portfolio company, Siairan, has completed over 100 million yuan financing, led by Qianji Capital and Shunwei Capital, with existing investors including Boxin Capital and Honghui Fund increasing their stakes [1] - The funds will primarily be used for the in-depth research and development of the company's first self-developed phacoemulsification and vitrectomy integrated machine, as well as to expand the product matrix of ophthalmic surgical equipment [1] - Siairan Medical, established in July 2022, has a core team with extensive industry experience and complete capabilities in R&D, production, and commercialization [1] Company Overview - Siairan Medical focuses on providing precise and intelligent minimally invasive surgical solutions for ophthalmology, aiming to break the monopoly of foreign companies in the high-end ophthalmic surgical instrument sector [1] - The company is addressing critical issues related to key surgical instruments and is currently developing products including the phacoemulsification and vitrectomy integrated machine and digital surgical microscopes [1] - Siairan Medical is committed to offering innovative and high-quality products and services to ophthalmologists and patients, promoting the advancement of ophthalmic medical technology [1]

Core Insights - SierraMedical, a leading domestic ophthalmic medical device innovation company, has successfully completed a new round of financing exceeding 100 million yuan, following a previous round in 2024 [1] - The financing was led by Qianji Capital and Shunwei Capital, with existing shareholders such as Boxin Capital and Honghui Fund also increasing their investments [1] - The funds will primarily be used for the in-depth research and development of the company's first self-developed phacoemulsification and vitrectomy integrated machine product line, as well as to enrich the company's ophthalmic surgical equipment product matrix [1] Company Development - SierraMedical aims to accelerate the import substitution of high-end ophthalmic instruments and the international expansion of its ophthalmic products [1] - The successful completion of this financing reflects investors' high recognition of SierraMedical's innovation capabilities and development prospects, providing strong momentum for the company's next stage of growth [1] - Established in July 2022, SierraMedical's core team possesses extensive industry experience and has complete capabilities in research, production, and commercialization [1] Industry Context - The domestic ophthalmic surgical equipment market has long relied on imported brands, but SierraMedical is gradually breaking this situation with its core proprietary technology [1] - The company focuses on providing precise and intelligent minimally invasive surgical treatment solutions for ophthalmology, aiming to break the monopoly of foreign enterprises in the high-end ophthalmic surgical instrument sector and address critical surgical instrument supply issues [1]